Physician profile
Nitya Alluri
NPI 1073712709
$1,360.43
in general payments reported to CMS, 2019-2025
18 companies · $1,165 in 2025
The $1,165 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $25.85 · 2024: $170 · 2025: $1,165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $690 · Consulting Fee: $645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $689.58 |
| Consulting Fee | $645.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $645.00 | 2025 | Monjuvi |
| Astellas Pharma US INC | $160.52 | 2024-2025 | Padcev, Vyloy |
| Celgene Corporation | $71.84 | 2025 | Opdivo, Opdualag, Reblozyl |
| Daiichi Sankyo INC. | $62.22 | 2025 | Enhertu, Datroway, Vanflyta |
| Genzyme Corporation | $60.42 | 2025 | |
| Merck Sharp & Dohme LLC | $50.00 | 2025 | Keytruda, Keytruda Qlex |
| Pfizer INC. | $47.33 | 2024-2025 | |
| Geron Corporation | $42.92 | 2025 | Rytelo |
| Acrotech Biopharma INC. | $36.78 | 2021-2025 | Beleodaq |
| Takeda Pharmaceuticals U.S.A., INC. | $29.86 | 2025 | Iclusig |
| E.R. Squibb & Sons, L.L.C. | $29.02 | 2025 | |
| Novocure INC. | $27.49 | 2025 | Optune Lua (Novottf-200t) |
| Novartis Pharmaceuticals Corporation | $26.39 | 2025 | |
| Aveo Pharmaceuticals, INC. | $20.82 | 2025 | |
| Puma Biotechnology, INC. | $20.45 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $17.45 | 2025 | Tecvayli, Talvey |
| Gilead Sciences, INC. | $11.92 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nitya Alluri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.